Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Photon Micro

This article was originally published in The Gray Sheet

Executive Summary

Downsized dual-chamber (DR) and single-chamber (VR) implantable cardioverter defibrillators will be launched in July following FDA approval via premarket approval application supplement, announced June 19. The rate-adaptive, 32-joule devices, which have a volume of 37 cc and 36 cc, respectively, offer features similar to the previous generation Photon, which has a volume of 46 cc and debuted in the U.S. in October 2000...

You may also be interested in...



CMS To Examine Clinical Benefit, Cost When Creating New OPPS Categories

The Centers for Medicare & Medicaid Services is asking manufacturers to provide examples of medical technologies for which transitional "pass-through" payments might be appropriate even if the device itself does not provide an obvious improvement in beneficiary outcomes over existing technologies

APACMed 2020: Healthineers Evolves Therapy Remit And Makes All Asia An Equal Priority

Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel